Venkata Atluri, PhD, MSc

Dr. Venkata Atluri completed four years as a postdoctoral fellow at the College of Medicine, Florida International University (2009–2013), before transitioning into a faculty role in the Department of Immunology and Nano-Medicine at FIU. In 2021, he furthered his academic career by joining the faculty at Noorda College of Osteopathic Medicine (COM) in Provo, Utah. Leveraging his extensive research expertise and passion for education, Dr. Atluri joined the Meritus School of Osteopathic Medicine.

Dr. Atluri's research is dedicated to elucidating the complex neuropathogenic mechanisms of HIV, with a particular focus on substance abuse. He pioneers the use of small-molecule drugs and nanotechnology-based drug delivery approaches, making significant contributions to the fields of HIV-associated neuropathology, neuroinflammation, and Alzheimer’s disease.

Courses Teaching:

• Medical Microbiology

Research/Areas of Interest:

• Role of inflammasome-mediated neuroinflammation in the neuropathogenesis of HIV infection and Alzheimer’s disease.
• Use of nanotechnology-based drug delivery approaches targeting HIV infection in the brain and Alzheimer’s disease.
• Use of gene-editing CRISPR/Cas9 technology targeting latent HIV infection in the brain.

Publications:

•  Recent Advances in Nanotechnology-Based Nanocarriers for the Diagnosis and Treatment of Ovarian Cancer. (2024, under preparation)
• Anti-HIV and Anti-Inflammasome Dual Activity of (R)-N-(1-Methyl-2-Hydroxyethyl)-13-(S)-Methyl-Arachidonate (AMG315): A Novel Chiral Potent Endocannabinoid Ligand. (2024, under preparation)
• Recent Advances, Status, and Opportunities of Magneto-Electric Nanocarriers for Biomedical Applications. Molecular Aspects of Medicine, 2022; 83: 101046. DOI: 10.1016/j.mam.2021.101046.
• Development of Multifunctional Biopolymeric Auto-Fluorescent Micro and Nanogels as a Platform for Biomedical Applications. Frontiers in Bioengineering and Biotechnology, 2020; 8:315. DOI: 10.3389/fbioe.2020.00315.
• Inhibition of Amyloid-Beta Production, Associated Neuroinflammation, and Histone Deacetylase 2-Mediated Epigenetic Modifications Prevent Neuropathology in Alzheimer’s Disease in vitro Model. Frontiers in Aging Neuroscience, 2020; 11:342. DOI: 10.3389/fnagi.2019.00342.